Financial Daily from THE HINDU group of publications
Saturday, Jun 11, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - Announcements
Marketing - New Products & Services


German Remedies launches new cancer drug

Our Bureau

Ahmedabad , June 10

GERMAN Remedies, part of the Zydus Group, has announced the launch of Fludarabine, a drug used for the treatment of chronic lymphocytic leukaemia (blood cancer).

The orally-administered drug, being marketed as Fludara Oral, has been introduced for the first time in the country and is a product of Berlex Inc, a US affiliate of Schering AG Germany, a Zydus Cadila executive told Business Line here.

Chronic lymphocytic leukaemia is a cancer of the lymphocytes. It is a serious, progressive disease, which has no cure and occurs mostly in people over 50 years of age.

"Fludarabine has emerged as one of the leading drugs for treatment - whether as a stand-alone therapy or in combination with other drugs. It helps control the disease by shortening the life span of existing leukaemia cells and interferes with the making of new DNA, thus preventing cancerous cells from growing. With this treatment, the remission can last for several years, thereby increasing the span of survival," the company executive said.

Till very recently, the only way to administer the drug was through an intra-venous injection, which is time consuming.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
World Park sets up hotel at Rameswaram


Tata group wants to invest heavily in Karnataka: Ratan
German Remedies launches new cancer drug
Ranbaxy acquires Spanish co's generic product portfolio
Jaypee plans 150-room hotel
RIL raises $350 m as multi-currency loan
Tata Steel gets $300-m IFC loan
Potential settlement of feud may not impact Reliance ratings: S&P
FCI bond issue oversubscribed
HPCL's Bhatinda refinery plan back on track
Knorr-Bremse opens facility in Pune
Euro plant starts production at Kutch
Yamaha India to invest Rs 200 cr over 3 yrs — `Several options' from global portfolio being considered for launch
Partha Dattagupta is Barista CEO


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line